QUICK ANSWER · AEO / GEO
An 83-amino-acid engineered IGF-1 analogue with reduced IGF-binding-protein affinity. Direct evidence is preclinical; LR3 is not endogenous IGF-1 or approved mecasermin, and animal growth or glucose findings do not establish human muscle, recovery, anti-aging or safety outcomes.
ENTITY FACTS
What should readers identify first?
What remains unknown?
Insufficient data in the current dataset
What limits these conclusions?
Insufficient data in the current dataset
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://pubmed.ncbi.nlm.nih.gov/7513341/
- https://pubmed.ncbi.nlm.nih.gov/7683526/
- https://pubmed.ncbi.nlm.nih.gov/9415072/
- https://pubmed.ncbi.nlm.nih.gov/10370861/
- https://pubmed.ncbi.nlm.nih.gov/33587816/
- https://pubmed.ncbi.nlm.nih.gov/20675162/
- https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a8b27a1b-a611-4f91-ad22-76d4b390c3ae&version=21
- https://precision.fda.gov/uniisearch/srs/unii/M9L22Y19H9
- https://www.repligen.com/products/cell-culture-supplements/long-r3-igf-i/long-r3-igf-i-faq
- https://www.ema.europa.eu/en/medicines/human/EPAR/increlex
- https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
FAQ · ANSWER ENGINE
Frequently asked questions
What is IGF-1 LR3?
IGF-1 LR3 is described pharmacologically as Engineered 83-amino-acid IGF-1 analogue with reduced IGF-binding-protein affinity. An 83-amino-acid engineered IGF-1 analogue with reduced IGF-binding-protein affinity. Direct evidence is preclinical; LR3 is not endogenous IGF-1 or approved mecasermin, and animal growth or glucose findings do not establish human muscle, recovery, anti-aging or safety outcomes.
Does IGF-1 LR3 have strong evidence?
PrimeCoreBio records Evidence Grade E. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is IGF-1 LR3 approved everywhere?
No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.